Guardant360® - Area of Application in Oncology

Guardant360^® CAN be used for:

Patients with solid tumors.
Patients with cancer in an advanced stage (stage III and IV).
Patients, whose tissue is unobtainable or whose biopsy yields an insufficient quantity for sequencing.
Patients with a progressive cancer.
Patients, who do not receive a therapy (chemotherapy or radiation therapy for example) at the moment.
Patients, who are planned to be treated with targeted drugs, since Guardant360^® can only predict the efficacy of targeted therapies. The efficacy of chemotherapies cannot be tested with Guardant360^® .
Patients, who want to monitor their cancer therapy (all forms of cancer therapy).
Patients, who have a progression despite therapy and want their tumor to be evaluated for present/newly formed mutations during therapy.

Patients with a hematological cancer (leukemia or lymphoma).
Patients with cancer stage I or II.
Patients receiving a chemotherapy or radiation therapy at the moment.
Patients, who require an efficacy prediction for other cancer therapies than targeted therapies like chemotherapies.